PARP inhibitors

[Nature Cell Biology] Using wild-type and a trapping-deficient poly (ADP-ribose) polymerase (PARP1) mutant combined with rapid immunoprecipitation mass spectrometry of endogenous proteins and Apex2 proximity labeling, investigators delineated mass spectrometry-based interactomes of trapped and non-trapped PARP1.

[Cell Death & Disease] Scientists found that repression of the oncogenic transcription factor FOXM1 using FOXM1 shRNA or FOXM1 inhibitor FDI-6 could sensitize BRCA-proficient TNBC to PARP inhibitor Olaparib in vitro and in vivo.

[Oncogene] Deregulation of CSN5, a putative androgen receptor (AR), could affect diverse cellular functions that contribute to tumor development. Inhibition of CSN5 repressed metabolic pathways, including oxidative phosphorylation and glycolysis in AR-negative prostate cancer cells.

[Nature Reviews Clinical Oncology] Scientists describe the current and upcoming therapeutic landscape of TNBC and discuss how an integrated view of the TNBC ecosystem can define different levels of risk and provide improved opportunities for tailoring treatment.

[Rakovina Therapeutics, Inc.] Rakovina Therapeutics, Inc. announced that the company has been selected to join a three year US $975,000 research program funded by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.

[Journal of Cellular and Molecular Medicine] Researchers demonstrated that mesenchymal–epithelial transition (MET) inhibition enhanced sensitivity of CRPC to poly adenosine diphosphate–ribose polymerase (PARP) inhibitors by suppressing the ATM/ATR and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathways.